De-activating the Ticking Bomb of Brain Diseases with Nanomedicines

Two Phase I, multicenter, sequential cohort, dose-escalation studies (NCT00539344 and NCT00539383) were carried out with ANG1005 in patients with malignant glioma (4) and with advanced solid tumors with brain metastases (5). Because the anticancer activity of ANG1005 was encouraging in patients with...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical Technology 2016-09, Vol.40 (9), p.26
Main Authors: Figueiredo, Melina, Leite, Diana M, Lalatsa, Aikaterini
Format: Magazinearticle
Language:English
Subjects:
Blood-brain barrier
Brain cancer
Brain diseases
Brain research
Breast cancer
Drug dosages
Ligands
Metastasis
Nanoparticles
Peptides
Permeability
Polyethylene glycol
Proteins
Studies
Toxicity
Toxicology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two Phase I, multicenter, sequential cohort, dose-escalation studies (NCT00539344 and NCT00539383) were carried out with ANG1005 in patients with malignant glioma (4) and with advanced solid tumors with brain metastases (5). Because the anticancer activity of ANG1005 was encouraging in patients with brain metastases from breast cancer (NCT01480583) in a Phase II, multicenter, open-label study, two additional Phase II trials have been performed to further verify its clinical activity in patients with recurrent high-grade glioma (NCT01967810) and breast cancer patients with recurrent brain metastases (NCT02048059). Spherical nucleic acid (SNA) nanomedicines comprised of gold nanoparticles, covalently functionalized with densely packed, highly oriented small interfering RNA duplexes have also been shown to result in intratumoral apoptosis, and decreased tumor burden and progression in xenografted mice, without adverse side effects after intravenous administration (16).
ISSN:1543-2521
2150-7376